Establishing test-retest reliability of an adapted [18F]fallypride imaging protocol in older people
Establishing test-retest reliability of an adapted [18F]fallypride imaging protocol in older people
复制标题
DOI：
10.1038/jcbfm.2013.55
复制
发表时间：
2013-07-01
影响因子：
6.3
通讯作者：
Reeves, Suzanne J.
中科院分区：
文献类型：
--
作者：
Dunn, Joel T.;Clark-Papasavas, Chloe;Reeves, Suzanne J.
[F-18]fallypride 是一种高亲和力多巴胺 D2/3 受体示踪剂，能够可靠地量化纹状体和皮质边缘区域的 D2/3 受体位点。然而，[F-18]fallypride 成像的转化潜力受到当前协议所需的冗长扫描过程（总共 3-4 小时的 60-80 分钟持续时间）的限制。我们研究的目的是通过减少单独扫描的持续时间，使 [F-18]fallypride 成像适用于患有神经系统和神经精神疾病的临床人群；并确定我们的适应方案在健康老年人中的可重复性和可靠性。八名参与者（五名男性和三名女性；平均年龄 = 75.87 +/- 4.39 岁）接受了两次扫描，间隔 4-6 周。 [F-18]fallypride结合电位根据三个采样时间期间收集的图像数据确定：0-30； 60-90；以及注射后 210-240 分钟。除前额叶区域外的所有区域均观察到高再现性和可靠性（重测变异性为 0.8），并且当采样时间减少到 20 分钟（0-20；70-90；220-240 分钟）时仍然如此。改编后的方案可用于涉及多巴胺的神经精神疾病，并且足够敏感，可以检测纹状体和边缘区域 2.7% 至 5.5% 之间的受试者内变化。
[F-18]fallypride is a high-affinity dopamine D2/3 receptor tracer with the ability to reliably quantify D2/3 receptor sites in both striatal and corticolimbic regions. The translational potential of [F-18]fallypride imaging is, however, limited by the lengthy scanning sessions (60-80 minutes duration over a total of 3-4 hours) required by current protocols. The aims of our study were to adapt [F-18]fallypride imaging for use in clinical populations with neurological and neuropsychiatric disorders, by reducing the duration of individual scanning sessions; and to establish the reproducibility and reliability of our adapted protocol in healthy older people. Eight participants (five male and three female; mean age = 75.87 +/- 4.39 years) were scanned twice, 4-6 weeks apart. [F-18]fallypride binding potential was determined from image data collected during three sampling times: 0-30; 60-90; and 210-240 minutes post injection. High reproducibility and reliability (test-retest variability 0.8) were observed in all but the prefrontal regions, and remained so when sampling times were reduced to 20 minutes (0-20; 70-90; 220-240 minutes). The adapted protocol is feasible for use across neuropsychiatric disorders in which dopamine has been implicated and is sufficiently sensitive to detect within-subject changes between 2.7% and 5.5% in striatal and limbic regions.